• Sun Pharma’s consolidated revenues for the quarter ended March (Q4FY22) were down 7% quarter-on-quarter (QoQ). On a year-on-year (YoY) basis, it witnessed a growth of 11%.
  • Its expenses for the quarter were down 2% QoQ and up 9% YoY
  • The company reported a net loss of Rs 2,277 crore in Q4FY22 as against a net profit of Rs 894 crore in Q4FY21.

Sun Pharma’s Financial Statements for Q4FY22::

(Rs, crores) Q4FY21 Q3FY22 Q4FY22 QoQ (%) YoY (%)
Total Income 8,634 10,296 9,560 -7% 11%
Total Expenses 7,058 7,829 7,700 -2% 9%
Profit before tax 903 2,466 -2,076 - -
Tax 55 335 147 -56% 167
Profit after tax 894 2,059 -2,277 - -
Earnings per share 3.7 8.6 -    

Data Source: BSE, Company announcements

Want to keep a tab on Indian listed companies? Open an account and get daily stock research updates from Kotak Securities.

The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results